Drugs / Heart-Protecting Musk Pill

Trials 2 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT05095922 Mar 2023 → May 2024 diabetic peripheral angiopathy, type 2 diabetes mellitus Affiliated Hospital of Nantong University Completed No outcome recorded
Phase 4 NCT01897805 Jul 2011 → Jun 2015 coronary artery disorder Shanghai Hutchison Pharmaceuticals Limited Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Heart-protecting Musk Pill ClinicalTrials.gov intervention name — accepted as the source's own label NCT01897805
1

NCT05095922

Known as HMP “Heart-Protecting Musk Pill (HMP) is a commonly used drug in clinical treatment” NCT05095922
Known as MUSKARDIA “Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial.” PMID 36386372 Oct 2022
Known as Shexiang Baoxin Pill Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial.” PMID 36386372 Oct 2022
Modality Traditional medicine (herbal / TCM) “To examine effects of of Heart-protecting Musk Pill, a traditional Chinese medicine, on clinical outcomes in patients with chronic stable coronary artery disease” NCT01897805
Route Oral “2 Heart-protecting Musk Pills each time, three times a day by mouth for 24 months” NCT01897805